BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30770779)

  • 21. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
    Wu Y; Xu W; Yang Y; Zhang Z
    Ann Clin Lab Sci; 2021 May; 51(3):310-320. PubMed ID: 34162560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.
    Zhang Q; Tang Q; Qin D; Yu L; Huang R; Lv G; Zou Z; Jiang XC; Zou C; Liu W; Luo J; Zhao Z; Muhammad S; Wang G; Chen YG; Wang X
    Mol Cell Biol; 2015 Mar; 35(6):988-1000. PubMed ID: 25582198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
    Zou J; Su H; Zou C; Liang X; Fei Z
    J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
    Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
    Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
    Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
    BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
    Sun ZY; Jian YK; Zhu HY; Li B
    Pathol Res Pract; 2019 Mar; 215(3):555-563. PubMed ID: 30661902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
    Yu S; Wang M; Zhang H; Guo X; Qin R
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer.
    Liu MM; Li Z; Han XD; Shi JH; Tu DY; Song W; Zhang J; Qiu XL; Ren Y; Zhen LL
    Sci Rep; 2017 Nov; 7(1):15929. PubMed ID: 29162879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
    Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
    Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.
    Li WF; Dai H; Ou Q; Zuo GQ; Liu CA
    Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.
    Wu ZH; Tao ZH; Zhang J; Li T; Ni C; Xie J; Zhang JF; Hu XC
    Tumour Biol; 2016 Jun; 37(6):7245-54. PubMed ID: 26666820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
    Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
    Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
    Liu T; Fang Y; Zhang H; Deng M; Gao B; Niu N; Yu J; Lee S; Kim J; Qin B; Xie F; Evans D; Wang L; Lou W; Lou Z
    Cancer Res; 2016 Feb; 76(3):572-81. PubMed ID: 26676747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Hong SK; Yang SY; Yin SH; Yang KX
    Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
    Mittal A; Chitkara D; Behrman SW; Mahato RI
    Biomaterials; 2014 Aug; 35(25):7077-87. PubMed ID: 24836307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
    Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
    Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.